Abeona Therapeutics Inc vs Twilio Inc — how do they compare? Abeona Therapeutics Inc trades at $7.34 (market cap $421.19M), while Twilio Inc trades at $248.6 (market cap $39.31B). The key difference: Twilio Inc is far larger — about 93.3× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | TWLO | |
|---|---|---|
Market Cap | $421.19M | $39.31B |
Sector | Health | Technology |
52-Week High | $7.45 | $255.95 |
52-Week Low | $4.17 | $95.23 |
Enterprise Value | $276.10M | $37.72B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Twilio (TWLO) trades at $250.06, up 3.64% with strong technical momentum and bullish moving average signals. The stock has delivered three consecutive earnings beats, with Q2 2026 EPS of $1.47 beating expectations by 11%. Revenue growth accelerated to 22% year-over-year in Q2, prompting management to raise full-year guidance to 18-18.5% growth. The company achieved record free cash flow generation with margins improving significantly.
Twilio presents compelling growth prospects with accelerating revenue and robust cash flow generation. However, elevated valuation multiples (P/E 35.35, EV/EBITDA 75.54) and overbought technical indicators suggest near-term consolidation risk. Analyst consensus remains strongly bullish with 77% buy ratings and $266.31 price target, representing 6.5% upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →